lecanemab

The FDA approved the use of Leqembi in January for patients with mild or early cases of dementia tied to Alzheimer’s. A year’s treatment runs about $26,500, and there are few options outside of self-pay.

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

Sarasota's Roskamp Institute was the first to discover a protein that tends to form clumps in the brains of people with Alzheimer's. A new drug has been shown to reduce it.

The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.